AI Article Synopsis
Article Abstract
Background: Although plasmapheresis has been recommended to reverse nephrotoxic elevations of serum free light chains (sFLCs), there are scant published data on removal of sFLC measured with modern assays.
Study Design And Methods: sFLC levels were recorded in two patients with myeloma-associated renal failure receiving multiple plasmapheresis procedures.
Results: In one patient, presenting with acute renal failure 8 months after diagnosis of kappa-LC myeloma, 16 plasmapheresis procedures neither reduced sFLC levels (percent removal ranging from -70% to +40%) nor improved renal function. In another patient who presented with leukemic immunoglobulin A-lambda myeloma and acute renal failure, sFLC decreased by 30 to 60 percent after each plasmapheresis procedure, but rebounded within 5 to 10 hours. Renal failure occurred despite plasmapheresis, and hemodialysis was required.
Conclusions: In both patients, plasmapheresis failed to effectively lower sFLC levels. The results provide initial biologic data supporting the conclusions of a recent randomized multicenter clinical trial in which plasmapheresis was an ineffective adjunct to chemotherapy for myeloma-associated acute renal failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1537-2995.2006.01143.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long term surgical outcomes following renal transplantation in Aotearoa New Zealand: the South Island Chapter.
ANZ J Surg
December 2024
Department of Vascular, Endovascular and Transplant Surgery, Christchurch Hospital, Christchurch, New Zealand.
Background: Over the last decade, there has been a steady increase in the number of patients diagnosed with end stage renal failure (ESRF). Renal transplant remains the best available treatment for ESRF. The aim of this study is to assess the surgical outcomes following renal transplantation in a single tertiary centre in Aotearoa New Zealand.
View Article and Find Full Text PDFChromatin State Maps of Blood Pressure-Relevant Renal Segments Reveal Potential Regulatory Role for SNPs.
Hypertension
December 2024
Versiti Blood Research Institute, Milwaukee, WI (A.R., C.S., S.R.).
Background: Hypertension or elevated blood pressure (BP) is a worldwide clinical challenge and the leading primary risk factor for kidney dysfunctions, heart failure, and cerebrovascular disease. The kidney is a central regulator of BP by maintaining sodium-water balance. Multiple genome-wide association studies revealed that BP is a heritable quantitative trait, modulated by several genetic, epigenetic, and environmental factors.
View Article and Find Full Text PDFAssociation of Social Isolation and Plasma Metabolites With the Risk of Venous Thromboembolism.
Arterioscler Thromb Vasc Biol
December 2024
Division of Nephrology and State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China. Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China.
Background: To explore the association of social isolation with venous thromboembolism (VTE) risk and the mediating role of metabolomics on this association.
Methods: Overall, 236 026 participants free of VTE and with complete metabolomics data at baseline from the UK Biobank were included. Social isolation was constructed based on the frequency of friend/family visits, weekly group activities, and living alone.
Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.
Diabetes Obes Metab
December 2024
The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Aim: To comprehensively evaluate the benefits and risks of glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP4i), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Materials And Methods: A systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to November 2023 to identify randomized cardiovascular and kidney outcome trials that enrolled adults with type 2 diabetes, heart failure, or chronic kidney disease and compared DPP4i, GLP-1RAs, or SGLT2i to placebo. Twenty-one outcomes (e.
Clinical course and outcome of adult patients with primary focal segmental glomerulosclerosis with kidney function loss on presentation.
World J Nephrol
December 2024
Department of Histopathology, Sindh Institute of Urology and Transplantation, Karachi 74200, Sindh, Pakistan.
Background: Kidney function loss or renal insufficiency indicated by elevated creatinine levels and/or an estimated glomerular filtration rate (eGFR) < 60 mL/minute/1.73 m² at presentation in patients with primary focal segmental glomerulosclerosis (FSGS) is commonly seen as a poor prognostic marker for kidney survival. However, a pre>vious study from our center suggested this may be due to hemodynamic factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!